Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Vericel Corporation

A Decade of SG&A Evolution: Exelixis, Inc. vs. Vericel Corporation

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Exelixis, Inc. and Vericel Corporation have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis, Inc. saw a staggering 967% increase in SG&A expenses, reflecting its aggressive expansion and strategic investments. In contrast, Vericel Corporation's SG&A expenses grew by approximately 779%, indicating a more measured approach to scaling operations.

By 2023, Exelixis, Inc.'s SG&A expenses were nearly five times higher than those of Vericel Corporation, highlighting its larger operational footprint. This divergence underscores the distinct strategic paths these companies have taken in the competitive biotech sector. As investors and industry watchers analyze these trends, the data offers a compelling narrative of growth, strategy, and market positioning.